Drug

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16
Auto-immuneClinical trial results

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio (Shanghai) Co., Ltd. (SHA: 688382) announced that the registrational Phase III clinical study of nomelcitinib (D‑2570), its self‑developed novel oral selective TYK2 JH2 inhibitor, has met its primary endpoint…

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Nuance Pharma Doses First Participant in REACH Phase III Trial of STG320 for House Dust Mite Allergic Rhinitis in China

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationClover Biopharmaceuticals

Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults

J&J’s Darzalex SC Becomes First Oncology Injectable in Europe Approved for Patient Self-Administration
CancerJ&J

J&J’s Darzalex SC Becomes First Oncology Injectable in Europe Approved for Patient Self-Administration

GlaxoSmithKlineGSK

GSK’s Bepirovirsen Receives EMA Review Acceptance for Chronic Hepatitis B, Pioneering Triple-Mechanism ASO Therapy

AstraZenecaClinical trial results

AstraZeneca’s Tozorakimab Reduces COPD Exacerbations in Phase III Trials, Targeting IL-33 in First-in-Class Approach

Show More